<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: agreement", fill: "#f0dc82"},
{source: "3: agreement", target: "3: either party notifies", fill: "#f0dc82"},
{source: "3: agreement", target: "4: VetTest ", fill: "#00416a"},
{source: "4: VetTest ", target: "4: supplied exclusively by", fill: "#00416a"},
{source: "4: supplied exclusively by", target: "4: under supply agreements with", fill: "#00416a"},
{source: "4: under supply agreements with", target: "4: Ortho ", fill: "#00416a"},
{source: "4: VetTest ", target: "10: manufactured", fill: "#e6e6fa"},
{source: "10: manufactured", target: "10: agreement", fill: "#e6e6fa"},
{source: "10: agreement", target: "10: Roche Diagnostics ", fill: "#e6e6fa"},
{source: "10: Roche Diagnostics ", target: "10: analyzers", fill: "#e6e6fa"},
{source: "10: analyzers", target: "10: December ", fill: "#e6e6fa"},
{source: "10: December ", target: "10: consumables", fill: "#e6e6fa"},
{source: "10: consumables", target: "10: parts through", fill: "#e6e6fa"},
{source: "10: manufactured", target: "20: future competition will become even", fill: "#4f666a"},
{source: "20: future competition will become even", target: "20: compete with", fill: "#4f666a"},
{source: "20: compete with", target: "20: technologies", fill: "#4f666a"},
{source: "20: technologies", target: "20: which could affect", fill: "#4f666a"},
{source: "20: which could affect", target: "20: marketability", fill: "#4f666a"},
{source: "20: future competition will become even", target: "22: compete with", fill: "#191970"},
{source: "22: compete with", target: "22: companies ranging from", fill: "#191970"},
{source: "22: companies ranging from", target: "22: businesses focused", fill: "#191970"},
{source: "22: businesses focused", target: "22: on animal health", fill: "#191970"},
{source: "22: on animal health", target: "22: pharmaceutical companies", fill: "#191970"},
{source: "22: compete with", target: "24: Academic ", fill: "#98ff98"},
{source: "24: Academic ", target: "24: institutions governmental agencies", fill: "#98ff98"},
{source: "24: institutions governmental agencies", target: "24: private research organizations also conduct research", fill: "#98ff98"},
{source: "24: private research organizations also conduct research", target: "24: activities", fill: "#98ff98"},
{source: "24: activities", target: "24: products on", fill: "#98ff98"},
{source: "24: products on", target: "24: through joint ventures", fill: "#98ff98"},
{source: "24: Academic ", target: "25: competitors", fill: "#d3d3d3"},
{source: "25: competitors", target: "25: substantially", fill: "#d3d3d3"},
{source: "25: substantially", target: "25: manufacturing", fill: "#d3d3d3"},
{source: "25: manufacturing", target: "25: development", fill: "#d3d3d3"},
{source: "25: competitors", target: "26: Competitive ", fill: "#9400d3"},
{source: "26: Competitive ", target: "26: different", fill: "#9400d3"},
{source: "26: different", target: "26: Veterinary ", fill: "#9400d3"},
{source: "26: Veterinary ", target: "26: diagnostic products", fill: "#9400d3"},
{source: "26: diagnostic products", target: "26: water testing products", fill: "#9400d3"},
{source: "26: Competitive ", target: "31: Veterinary ", fill: "#c72"},
{source: "31: Veterinary ", target: "31: pharmaceuticals", fill: "#c72"},
{source: "31: Veterinary ", target: "44: facility license from", fill: "#cfb53b"},
{source: "44: facility license from", target: "44: APHIS ", fill: "#cfb53b"},
{source: "44: APHIS ", target: "44: manufacture", fill: "#cfb53b"},
{source: "44: facility license from", target: "73: comply with legal", fill: "#f2003c"},
{source: "73: comply with legal", target: "73: regulatory requirements", fill: "#f2003c"},
{source: "73: regulatory requirements", target: "73: manufacture", fill: "#f2003c"},
{source: "73: manufacture", target: "73: countries could", fill: "#f2003c"},
{source: "73: countries could", target: "73: sanctions against us", fill: "#f2003c"},
{source: "73: sanctions against us", target: "73: products from", fill: "#f2003c"},
{source: "73: products from", target: "73: which could", fill: "#f2003c"},
{source: "73: which could", target: "73: operations", fill: "#f2003c"},
{source: "73: comply with legal", target: "START_HERE", fill: "#f2003c"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Research and Consulting Services</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Oil and Gas Storage and Transportation</td>
    </tr>
    <tr>
      <td>Oil and Gas Refining and Marketing and Transportation</td>
    </tr>
    <tr>
      <td>Transportation</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Negotiation</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenuptial_agreement">Prenuptial agreement</a></td>
      <td>A prenuptial agreement, antenuptial agreement, or premarital agreement (commonly referred to as a prenup), is a written contract entered into by a couple prior to marriage or a civil union that enables them to select and control many of the legal rights they acquire upon marrying, and what happens when their marriage eventually ends by death or divorce. Couples enter into a written prenuptial agreement to supersede many of the default marital laws that would otherwise apply in the event of divorce, such as the laws that govern the division of property, retirement benefits, savings, and the right to seek alimony (spousal support) with agreed-upon terms that provide certainty and clarify their marital rights.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/TRIPS_Agreement">TRIPS Agreement</a></td>
      <td>The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is an international legal agreement between all the member nations of the World Trade Organization (WTO). It establishes minimum standards for the regulation by national governments of different forms of intellectual property (IP) as applied to nationals of other WTO member nations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-disclosure_agreement">Non-disclosure agreement</a></td>
      <td>A non-disclosure agreement (NDA), also known as a confidentiality agreement (CA), confidential disclosure agreement (CDA), proprietary information agreement (PIA), secrecy agreement (SA), or non-disparagement agreement, is a legal contract or part of a contract between at least two parties that outlines confidential material, knowledge, or information that the parties wish to share with one another for certain purposes, but wish to restrict access to. Doctor–patient confidentiality (physician–patient privilege), attorney–client privilege, priest–penitent privilege and bank–client confidentiality agreements are examples of NDAs, which are often not enshrined in a written contract between the parties.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Minsk_agreements">Minsk agreements</a></td>
      <td>The Minsk agreements were a series of international agreements which sought to end the war in the Donbas region of Ukraine. The first, known as the Minsk Protocol, was drafted in 2014 by the Trilateral Contact Group on Ukraine, consisting of Ukraine, Russia, and the Organization for Security and Co-operation in Europe (OSCE), with mediation by the leaders of France and Germany in the so-called Normandy Format.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Veterinarian">Veterinarian</a></td>
      <td>A veterinarian (vet), also known as a veterinary surgeon or veterinary physician, is a medical professional who practices veterinary medicine. They manage a wide range of health conditions and injuries in non-human animals.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consumables">Consumables</a></td>
      <td>Consumables (also known as consumable goods, non-durable goods, or soft goods) are goods that are intended to be consumed. People have, for example, always consumed food and water.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consumed">Consumed</a></td>
      <td>Consumables (also known as consumable goods, non-durable goods, or soft goods) are goods that are intended to be consumed. People have, for example, always consumed food and water.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consumability">Consumability</a></td>
      <td>A concept recently championed by International Business Machines (IBM), consumability is a description of customers' end-to-end experience with technology solutions (although the concept could easily apply to almost anything).  The tasks associated with consumability start before the consumer purchases a product and continue until the customer stops using the product.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_countries_by_oil_consumption">List of countries by oil consumption</a></td>
      <td>This is a list of countries by oil consumption.\nIn 2020 total worldwide oil consumption is expected to drop by 9% year over year compared to 2019 due to the COVID-19 pandemic according to the International Energy Agency (IEA).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consuming_Impulse">Consuming Impulse</a></td>
      <td>Consuming Impulse (stylized as Consvming Impvlse) is the second album by Dutch death metal band Pestilence, released in 1989. While retaining some of the thrash metal elements from its predecessor Malleus Maleficarum (1988), Consuming Impulse saw the band progress further towards the traditional death metal genre with progressive influences; this can be seen as one of the earliest examples of technical death metal, a subgenre that would be used and expanded on Pestilence's subsequent albums.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consumed_(novel)">Consumed (novel)</a></td>
      <td>Consumed is the first novel by the Canadian filmmaker, screenwriter and actor David Cronenberg. The novel is driven by a globe-trotting, photojournalist couple, that pursue stories featuring rather unusual people.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Consuming_Flame">The Consuming Flame</a></td>
      <td>The Consuming Flame: Open Exercises in Group Form is the twelfth studio album by experimental electronic music duo Matmos, released on August 21, 2020 through Thrill Jockey.\n\n\n== Critical reception ==\nThe Consuming Flame received "universal acclaim" according to album review aggregator Metacritic.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_cleaning">Commercial cleaning</a></td>
      <td>Commercial cleaning companies are contracted to carry out cleaning jobs in a variety of premises.\n\n\n== Cleaning techniques and equipment ==\n\nCommercial office cleaning companies use a wide variety of cleaning methods, chemicals, and equipment to facilitate and expedite the cleaning process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Veterinary_medicine">Veterinary medicine</a></td>
      <td>Veterinary medicine is the branch of medicine that deals with the prevention, control, diagnosis, and treatment of disease, disorder, and injury in animals. Along with this, it deals with animal rearing, husbandry, breeding, research on nutrition, and product development.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_industry">Pharmaceutical industry</a></td>
      <td>The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate symptoms.  Pharmaceutical companies may deal in generic or brand medications and medical devices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Veterinary_specialties">Veterinary specialties</a></td>
      <td>A veterinary specialist is a veterinarian who specializes in a clinical field of veterinary medicine.\nA veterinary specialist may be consulted when an animal's condition requires specialized care above and beyond that which a regular veterinarian can offer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Veterinary_surgery">Veterinary surgery</a></td>
      <td>Veterinary surgery is surgery performed on animals by veterinarians, whereby the procedures fall into three broad categories: orthopaedics (bones, joints, muscles), soft tissue surgery (skin, body cavities, cardiovascular system, GI/urogenital/respiratory tracts), and neurosurgery.  Advanced surgical procedures such as joint replacement (total hip, knee and elbow replacement), fracture repair, stabilization of cranial cruciate ligament deficiency, oncologic (cancer) surgery, herniated disc treatment, complicated gastrointestinal or urogenital procedures, kidney transplant, skin grafts, complicated wound management, and minimally invasive procedures (arthroscopy, laparoscopy, thoracoscopy) are performed by veterinary surgeons (as registered in their jurisdiction).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Veterinary_obstetrics">Veterinary obstetrics</a></td>
      <td>Veterinary obstetrics are the obstetrical methods used in veterinary medicine, which are quite different from those of human medicine. Veterinary obstetrics is a branch of veterinary medicine that deals with medical and surgical care together with manipulations of the female animals in breeding, gestation, labor, puerperium (postpartum period), and care of the newborn.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Veterinary_pathology">Veterinary pathology</a></td>
      <td>Veterinary pathologists are veterinarians who specialize in the diagnosis of diseases through the examination of animal tissue and body fluids. Like medical pathology, veterinary pathology is divided into two branches, anatomical pathology and clinical pathology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_schools_of_veterinary_medicine">List of schools of veterinary medicine</a></td>
      <td>This is a list of veterinary schools throughout the world by country.\n\n\n== Afghanistan ==\nKabul University Veterinary Science Faculty\nHerat University Veterinary Science Faculty\nNangarhar University Veterinary Science Faculty\nKunduz University Veterinary Science Faculty\nKhost University Veterinary Science Faculty\nMazar-e-Sharif University Veterinary Science Faculty\nHelman University Veterinary Science Faculty\nKandahar University Veterinary Science Faculty\nBamyan University Veterinary Science Department\n\n\n== Albania ==\nAgricultural University of Tirana Faculty of Veterinary Medicine\nWorldWide University Veterinary Science Programme\n\n\n== Algeria ==\nHigher National Veterinary School\nSaad Dahlab University of Blida Department of Veterinary Sciences\nUniversity of Batna Veterinary Department\nUniversity of Ibn Khaldoun, Tiaret\nUniversity of Mentouri – Constantine Faculty of Natural and Life Sciences\nUniversity of Taref Veterinary Departement\n\n\n== Angola ==\nJosé Eduardo dos Santos University Faculty of Veterinary Medicine\n\n\n== Argentina ==\nCatholic University of Cordoba Faculty of Agricultural and Veterinary Sciences\nCatholic University of Cuyo, San Luis campus Faculty of Veterinary Sciences\nJuan Agustín Maza University Faculty of Veterinary and Environmental Sciences\nNational University of Central Buenos Aires Faculty of Veterinary Sciences\nNational University of La Pampa Faculty of Veterinary Sciences\nNational University of La Plata Faculty of Veterinary Sciences\nNational University of the Littoral Faculty of Veterinary Sciences\nNational University of the Northeast Faculty of Veterinary Sciences\nNational University of Río Cuarto Faculty of Agronomy and Veterinary Sciences\nNational University of Rosario Faculty of Veterinary Sciences\nNational University of Tucumán Faculty of Veterinary Sciences\nUniversity of Buenos Aires Faculty of Veterinary Sciences\nUniversity of El Salvador Veterinary Medicine Course\nNational University of Villa María Instituto Académico Pedagógico de Ciencias Básicas y Applicadas\n\n\n== Australia ==\nAustralia has seven schools of veterinary medicine:\n\nCharles Sturt University School of Animal and Veterinary Sciences\nJames Cook University, College of Public Health, Medical and Veterinary Sciences\nMurdoch University School of Veterinary and Life Sciences\nUniversity of Adelaide School of Veterinary Science\nUniversity of Melbourne Melbourne Veterinary School\nUniversity of Queensland School of Veterinary Science\nUniversity of Sydney Faculty of Veterinary Science\n\n\n== Austria ==\nUniversity of Veterinary Medicine Vienna\n\n\n== Bangladesh ==\nBangladesh Agricultural University Faculty of Veterinary Science\nSylhet Agricultural University Faculty of Veterinary, Animal and Biomedical Sciences\nBangabandhu Sheikh Mujibur Rahman Agricultural University Faculty of Veterinary Medicine and Animal Science\nChittagong Veterinary and Animal Sciences University\nHajee Mohammad Danesh Science &amp; Technology University Faculty of Veterinary &amp; Animal Science\nPatuakhali Science and Technology University Faculty of Animal science and veterinary medicine, Barishal campus\nJhenaidah Government Veterinary College, Jhenidah, Bangladesh\nRajshahi University Faculty of  Veterinary &amp; Animal Sciences\nSher-e-Bangla Agricultural University Faculty of Animal Science and Veterinary Medicine\nGono University Faculty of Veterinary &amp; Animal Sciences(Private University)\nKhulna Agricultural University, khulna\nSirajganj Government Veterinary college\nBangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj\n\n\n== Belarus ==\nGorkovskii Agricultural Institute\nVitebsk State Academy of Veterinary Medicine\n\n\n== Belgium ==\nFaculty of Veterinary Medicine, University of Liège, Liège\nFaculty of Veterinary Medicine, Ghent University, Ghent\nSchool of Veterinary Medicine, Faculty of Science, UCLouvain, Louvain-la-Neuve (undergraduate only)\nFaculty of Medicine, Université libre de Bruxelles, Anderlecht (undergraduate only)\n\nFaculty of Pharmaceutical, Biomedial, and Veterinary Science, University of Antwerp, Antwerp (undergraduate only)\n\n\n== Bolivia ==\nAutonomous University of Beni "José Ballivián" Faculty of Livestock Sciences\nGabriel René Moreno Autonomous University Veterinary Sciences Faculty\n\n\n== Bosnia and Herzegovina ==\nUniversity of Sarajevo Veterinary Faculty\n\n\n== Brazil ==\nFederal University of Bahia\nCenter of Higher Teaching of Campos Gerais Veterinary Medicine\nFederal University of Goiás Veterinary and Husbandry School\nFederal University of Lavras Department of Veterinary Medicine\nFederal University of Minas Gerais\nFederal University of Pampa\nFederal University of Paraíba Center of Agricultural Sciences\nFederal University of Paraná\nFederal University of Pelotas College of Veterinary Medicine\nFederal University of Pernambuco\nFederal University of Rio Grande do Sul Faculty of Veterinary Sciences\nFederal University of Santa Maria Veterinary Medicine\nFederal University of Viçosa Veterinary Department\nFluminense Federal University\nPaulista Júlio State University of Mesquita Filho, Botucatu campus Faculty of Veterinary Medicine and Husbandry\nPaulista Júlio State University of Mesquita Filho, Jaboticabal campus Faculty of Veterinary Medicine and Husbandry\nPontifical Catholic University of Paraná School of Agriculture and Veterinary Medicine\nRural Federal University of Rio de Janeiro\nSanta Catarina State University Veterinary and Agricultural Center\nUniversidade Estadual de Maringá\nUNICENTRO – Universidade Estadual do Centro-Oeste do Paraná\nUniversity of Brasília Faculty of Agronomy and Veterinary Medicine\nUniversity of São Paulo Faculty of Veterinary Medicine\nVila Velha University\nUniversidade Estadual do Ceará/ Faculdade de Veterinária (UECE/FAVET)\n\n\n== Bulgaria ==\nTrakia University Faculty of Veterinary Medicine\nUniversity of Forestry, Sofia Faculty of Veterinary Medicine\n\n\n== Canada ==\nCanada has five schools of veterinary medicine:\n\nAtlantic Veterinary College, University of Prince Edward Island\nOntario Veterinary College, University of Guelph\nUniversité de Montréal Faculty of Veterinary Medicine\nUniversity of Calgary Faculty of Veterinary Medicine\nWestern College of Veterinary Medicine, University of Saskatchewan\n\n\n== Chile ==\nAustral University of Chile Faculty of Veterinary Sciences\nMayor University Veterinary Medicine\nSan Sebastián University Veterinary Medicine\nSanto Tomás University Veterinary Medicine\nUniversity of the Americas Faculty of Veterinary Medicine and Agronomy\nUniversity of Chile Faculty of Veterinary Sciences and Livestock\nUniversity of Concepción Faculty of Veterinary Sciences\n\n\n== China ==\nCollege of Animal Husbandry and Veterinary Medicine Shenyang Agricultural University China\nCollege of Animal Science and Technology Anhui Agricultural University Hefei city China\nCollege of Animal Science and Technology Animal diseases institute China\nCollege of Animal Science and Veterinary Medicine Heilongjiang Bayi Agricultural University China\nCollege of Animal Science and Veterinary Medicine Shanxi Agricultural University China\nCollege of Veterinary Medicine HeBei Agricultural China\nCollege of Veterinary Medicine Huazhong Agricultural University China\nCollege of Veterinary Medicine Northwest A&amp;F University China\nCollege of Veterinary Medicine Southwest Uniwersity China\nDepartment of Animal Medicine Agricultural college of Yanbian Uniweisity China\nLife Science and Engineering College Northwest University for Nationalities China\nVeterinary College Northeast Agricultural University China\nVeterinary Medicine Department, College of Life Science and Technology Southwest University for nationalities China\nAnimal science and veterinary medicine college Tianjin agricultural University China\nChina Agricultural University College of Veterinary Medicine Beijing China\nCollege of Animal Science and Technolog Guangxi University China\nCollege of Animal Science and Technolog Qingdao Agricultural University China\nCollege of Animal science and technology HeNan University of science and technology China\nCollege of Animal Science and Veterinary Medicine Henan institute of science and technology China\nCollege of Animal Science/Veterinary Medicine Shandong Agricultural University China\nCollege of Veterinary Medicine Inner Mongolia Agricultural University China\nCollege of Veterinary Medicine Jiangxi Agricultural University China\nCollege of Veterinary Medicine Yangzhou University China\nCollege of Veterinary Medicine, South China Agricultural University China\nCollege of Veterinary Medicine.Sicau Sichuan Agriculture University China\nHenan Agricultural University, College of Animal Husbandry and Veterinary Science Henan China\nHuazhong Agricultural University, College of Veterinary Medicine Wuhan · Hubei Province China\nJiangsu–Yangzhou University, College of Veterinary Medicine Yangzhou, Jiangsu China                          * The College of Veterinary Medicine at Nanjing Agricultural University (NAU) China\nZhejiang Agricultural University College of Animal Science &amp; Veterinary Medicine Hangzhou China\n\n\n== Costa Rica ==\nEscuela de Medicina y Cirugía Veterinaria San Francisco de Asís, Universidad Veritas\nNational University of Costa Rica School of Veterinary Medicine\n\n\n== Croatia ==\nUniversity of Zagreb Faculty of Veterinary Medicine\n\n\n== Czech Republic ==\nUniversity of Veterinary and Pharmaceutical Sciences Brno\n\n\n== Denmark ==\nRoyal Veterinary and Agricultural University (1856–2007)\nUCPH School of Veterinary Medicine and Animal Science (2012–)\n\n\n== Dominica ==\nSt.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medication">Medication</a></td>
      <td>Meditation is a practice in which an individual uses a technique – such as mindfulness, or focusing the mind on a particular object, thought, or activity – to train attention and awareness, and achieve a mentally clear and emotionally calm and stable state.Meditation  is practiced in numerous religious traditions. The earliest records of meditation (dhyana) are found in the Upanishads of Hindu philosophy, and meditation plays a salient role in the contemplative repertoire of Buddhism and Hinduism.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Teva_Pharmaceuticals">Teva Pharmaceuticals</a></td>
      <td>Teva Pharmaceutical Industries Ltd. (also known as Teva Pharmaceuticals) is an Israeli multinational pharmaceutical company with headquarters in Petah Tikva, Israel.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutics">Pharmaceutics</a></td>
      <td>Pharmaceutics is the discipline of pharmacy that deals with the process of turning a new chemical entity (NCE) or old drugs into a medication to be used safely and effectively by patients.  It is also called the science of dosage form design.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Grasshopper_Manufacture">Grasshopper Manufacture</a></td>
      <td>Grasshopper Manufacture Inc. (株式会社グラスホッパー・マニファクチュア, Kabushiki Gaisha Gurasuhoppā Manifakuchua) is a Japanese video game developer founded on March 30, 1998 by Goichi Suda.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_d'horlogerie">Manufacture d'horlogerie</a></td>
      <td>Manufacture d'horlogerie (meaning "watchmaking manufacturer") is a French language term of horology that has also been adopted in the English language as a loanword. In horology, the term is usually encountered in its abbreviated form manufacture.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gobelins_Manufactory">Gobelins Manufactory</a></td>
      <td>The Gobelins Manufactory (French: Manufacture des Gobelins) is a historic tapestry factory in Paris, France. It is located at 42 avenue des Gobelins, near Les Gobelins métro station in the 13th arrondissement of Paris.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Build-on-demand">Build-on-demand</a></td>
      <td>Build-on-demand or manufacturing on demand (MOD) refers to a manufacturing process where goods are produced only when or as they are required. This allows scalability and adjustable assemblies depending on the current needs of the part requestor or client.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_nationale_de_Sèvres">Manufacture nationale de Sèvres</a></td>
      <td>The Manufacture nationale de Sèvres is one of the principal European porcelain factories. It is located in Sèvres, Hauts-de-Seine, France.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Design_for_manufacturability">Design for manufacturability</a></td>
      <td>Design for manufacturability (also sometimes known as design for manufacturing or DFM) is the general engineering practice of designing products in such a way that they are easy to manufacture. The concept exists in almost all engineering disciplines, but the implementation differs widely depending on the manufacturing technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_operations">Special operations</a></td>
      <td>Special operations (S.O.) are military activities conducted, according to NATO, by "specially designated, organized, selected, trained, and equipped forces using unconventional techniques and modes of employment". Special operations may include reconnaissance, unconventional warfare, and counter-terrorism actions, and are typically conducted by small groups of highly-trained personnel, emphasizing sufficiency, stealth, speed, and tactical coordination, commonly known as "special forces".</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>IDEXX LABORATORIES INC /DE      Item 1A <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>”                                         6       _________________________________________________________________       PRODUCTION AND SUPPLY               VetTest^® Chemistry Analyzers are <font color="blue"><font color="blue">manufacture</font>d</font> for us by Tokyo Parts     Industrial Company, Ltd</td>
    </tr>
    <tr>
      <td>under an <font color="blue">agreement</font> that renews annually unless     <font color="blue">either party notifies</font> the other of its decision not to renew</td>
    </tr>
    <tr>
      <td>VetTest^®     slides are <font color="blue">supplied exclusively by</font> Ortho under supply <font color="blue">agreement</font>s with <font color="blue">Ortho     </font>(the  “Ortho  Agreements”)</td>
    </tr>
    <tr>
      <td>We  are  required  to purchase all of our     <font color="blue">requirements</font> for our <font color="blue">current menu</font> of VetTest^® <font color="blue">slides from</font> Ortho to the     extent Ortho is able to supply those <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>In addition, we have     committed to <font color="blue">minimum annual purchase volumes</font> of certain VetTest^® slides     through 2010</td>
    </tr>
    <tr>
      <td><font color="blue">The Ortho Agreements </font>expire on <font color="blue">December </font>31, 2020</td>
    </tr>
    <tr>
      <td>The VetAutoread™ Hematology Analyzer is <font color="blue"><font color="blue">manufacture</font>d</font> for us by QBC     Diagnostics, Inc</td>
    </tr>
    <tr>
      <td>(“QBCD”) under a supply <font color="blue">agreement</font> that <font color="blue">expires on</font> <font color="blue">December </font>    31, 2020</td>
    </tr>
    <tr>
      <td>The VetLyte^® Electrolyte Analyzer is <font color="blue"><font color="blue">manufacture</font>d</font> for us by Roche     Diagnostics Corporation under an <font color="blue">agreement</font> that requires <font color="blue"><font color="blue">Roche Diagnostics </font>    </font>to supply <font color="blue">analyzers</font> through <font color="blue">December </font>31, 2006, and <font color="blue">consumables</font> and spare     <font color="blue">parts through</font> <font color="blue">December </font>31, 2013</td>
    </tr>
    <tr>
      <td>The VetStat™ Electrolyte and Blood Gas     Analyzer is <font color="blue"><font color="blue">manufacture</font>d</font> for us by Osmetech, Inc</td>
    </tr>
    <tr>
      <td>under an <font color="blue">agreement</font> that     requires Osmetech to supply <font color="blue">analyzers</font> and <font color="blue">consumables</font> through 2015 and we     have an option to extend this <font color="blue">agreement</font> for an <font color="blue">additional four years</font></td>
    </tr>
    <tr>
      <td>We     have <font color="blue">certain minimum <font color="blue">purchase <font color="blue">obligations</font></font> under</font> these <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>We <font color="blue">purchase certain</font> other products, raw materials and <font color="blue">components</font>     from  a  single  supplier</td>
    </tr>
    <tr>
      <td>These  include  <font color="blue">active <font color="blue">ingredients</font></font> for our     <font color="blue"><font color="blue">pharmaceutical</font> products</font>, certain digital <font color="blue">radiography</font> systems, instrument     <font color="blue">consumables</font>, and certain <font color="blue">components</font> used in our SNAP^® <font color="blue">rapid assay devices</font>,     <font color="blue">water <font color="blue">testing products</font></font> and LaserCyte^® Hematology Analyzers</td>
    </tr>
    <tr>
      <td>We have in the     past  been  successful in ensuring an <font color="blue">uninterrupted supply</font> of products     <font color="blue">purchased from single source suppliers</font></td>
    </tr>
    <tr>
      <td>However, there can be no assurance     that <font color="blue">uninterrupted supply</font> can be maintained if these <font color="blue">agreement</font>s terminate     for  any  reason  or our <font color="blue">suppliers otherwise</font> are unable to satisfy our     <font color="blue">requirements</font> for products</td>
    </tr>
    <tr>
      <td>We do not <font color="blue">generally</font> maintain <font color="blue">significant backlog</font> and believe that     our <font color="blue">backlog at</font> any <font color="blue">particular date historically</font> has not <font color="blue">been indicative</font> of     <font color="blue">future sales</font></td>
    </tr>
    <tr>
      <td>COMPETITION               We <font color="blue">face intense competition within</font> the markets in which we sell our     products and services</td>
    </tr>
    <tr>
      <td>We expect that <font color="blue">future competition will become even</font>     more intense, and that we will have to <font color="blue">compete with</font> changing <font color="blue">technologies</font>,     <font color="blue"><font color="blue">which could</font> affect</font> the <font color="blue">marketability</font> of our products and services</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">competitive position also will depend on</font> our ability to develop <font color="blue">proprietary</font>     products, attract and retain <font color="blue">qualified scientific</font> and other personnel,     develop and implement production and marketing plans, obtain or license     <font color="blue">patent rights</font>, and obtain <font color="blue">adequate capital resources</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">compete with</font> many <font color="blue">companies ranging from</font> small <font color="blue"><font color="blue">businesses</font> focused</font>     <font color="blue">on animal health</font> to large <font color="blue"><font color="blue">pharmaceutical</font> companies</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitors</font> vary</font> in     our <font color="blue"><font color="blue">different</font> markets</font></td>
    </tr>
    <tr>
      <td><font color="blue">Academic </font>institutions, governmental agencies and     other  public and <font color="blue">private research organizations also conduct research</font>     <font color="blue">activities</font> and may commercialize products, <font color="blue">which could</font> <font color="blue">compete with</font> our     products, on their own or <font color="blue">through joint ventures</font></td>
    </tr>
    <tr>
      <td>Some of our <font color="blue">competitors</font>     have <font color="blue">substantially</font> greater capital, <font color="blue">manufacturing</font>, marketing, and research     and <font color="blue">development</font> resources than we do</td>
    </tr>
    <tr>
      <td><font color="blue">Competitive </font>factors in our <font color="blue">different</font> business areas are detailed     below:       • <font color="blue">Veterinary </font><font color="blue"><font color="blue">diagnostic</font> products</font> and food and <font color="blue">water <font color="blue">testing products</font></font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">compete <font color="blue">primarily on</font></font> the basis of the ease of use, speed, accuracy and other     <font color="blue">performance <font color="blue">characteristics</font></font> of our products and services (including unique     tests), the breadth of our <font color="blue">product line</font> and services, the <font color="blue">effectiveness</font> of     our sales and <font color="blue"><font color="blue">distribution</font> channels</font>, the quality of our technical and     <font color="blue">customer service</font>, and our <font color="blue">pricing relative</font> to the value of our products</td>
    </tr>
    <tr>
      <td>• <font color="blue">Veterinary </font><font color="blue">laboratory</font> and <font color="blue">consulting services</font></td>
    </tr>
    <tr>
      <td>In this market, we compete     <font color="blue">primarily on</font> the basis of quality, service, <font color="blue">technology</font>, and our pricing     relative to the value of our services</td>
    </tr>
    <tr>
      <td>We compete in <font color="blue">certain geographic</font>     locations in the US with Antech Diagnostics, a unit of VCA Antech, Inc</td>
    </tr>
    <tr>
      <td>• <font color="blue">Veterinary </font><font color="blue"><font color="blue">pharmaceutical</font>s</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">compete <font color="blue">primarily on</font></font> the basis of the     <font color="blue">performance <font color="blue">characteristics</font></font> of our products</td>
    </tr>
    <tr>
      <td>We     <font color="blue">compete <font color="blue">primarily on</font></font> the basis of ease of use, <font color="blue">connectivity</font> to equipment and     other systems, <font color="blue">performance <font color="blue">characteristics</font></font>, <font color="blue">effectiveness</font> of our customer     service, information handling <font color="blue">capabilities</font>, advances in <font color="blue">technologies</font>, and     our <font color="blue">pricing relative</font> to the value of our products and services</td>
    </tr>
    <tr>
      <td>7       _________________________________________________________________       GOVERNMENT REGULATION               Many of our products are subject to regulation by US and foreign     <font color="blue">regulatory</font>  agencies</td>
    </tr>
    <tr>
      <td>The following is a description of the principal     <font color="blue"><font color="blue">regulations</font> affecting</font> our <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td><font color="blue">Veterinary </font><font color="blue"><font color="blue">diagnostic</font> products</font></td>
    </tr>
    <tr>
      <td>Most <font color="blue"><font color="blue">diagnostic</font> tests</font> for animal     <font color="blue">health applications</font> are <font color="blue"><font color="blue">veterinary</font> biological products</font> that are regulated in     the US by the Center for <font color="blue">Veterinary </font>Biologics within the USDA Animal and     Plant Health Inspection Service (“APHIS”)</td>
    </tr>
    <tr>
      <td><font color="blue">The APHIS </font><font color="blue">regulatory</font> approval     process  involves  the  submission  of  product  performance  data and     <font color="blue">manufacturing</font> documentation</td>
    </tr>
    <tr>
      <td><font color="blue">Following </font><font color="blue">regulatory</font> approval to market a     product, APHIS requires that each lot of product be submitted for review     before release to customers</td>
    </tr>
    <tr>
      <td>In addition, APHIS requires <font color="blue">special approval</font> to     <font color="blue">market products</font> where test results are used in part for government-mandated     <font color="blue">disease <font color="blue">management</font> programs</font></td>
    </tr>
    <tr>
      <td>A number of <font color="blue"><font color="blue">foreign governments</font> accept</font> <font color="blue">APHIS     </font><font color="blue">approval as</font> part of their separate <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td>However, compliance     with  an  extensive  <font color="blue">regulatory</font> process is required in <font color="blue">connection with</font>     marketing <font color="blue"><font color="blue">diagnostic</font> products</font> in Japan, Germany, the Netherlands and many     other countries</td>
    </tr>
    <tr>
      <td>We also are required to have a <font color="blue">facility license from</font> <font color="blue">APHIS     </font>to <font color="blue">manufacture</font> USDA-licensed products</td>
    </tr>
    <tr>
      <td>We have obtained such a license for     our <font color="blue">manufacturing</font> facility in Westbrook, Maine and Memphis, Tennessee</td>
    </tr>
    <tr>
      <td>Our instrument systems are <font color="blue">medical devices <font color="blue">regulated by</font></font> the US     Food and Drug Administration (“FDA”) under the Food, Drug and Cosmetics Act     (the “FDC Act”)</td>
    </tr>
    <tr>
      <td>While the sale of these products does not require premarket     <font color="blue">approval by</font> FDA and does not subject us to the FDA’s Good <font color="blue">Manufacturing </font>    Practices <font color="blue">regulations</font> (“GMPs”), these <font color="blue">products must</font> not be <font color="blue">adulterated</font> or     <font color="blue">misbranded under</font> the FDC Act</td>
    </tr>
    <tr>
      <td><font color="blue">Veterinary </font><font color="blue"><font color="blue">pharmaceutical</font>s</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font> and sale of <font color="blue">veterinary</font>     <font color="blue"><font color="blue">pharmaceutical</font>s</font> are <font color="blue">regulated by</font> the Center for <font color="blue">Veterinary </font>Medicine (“CVM”)     of the FDA A <font color="blue">new animal drug may</font> not be <font color="blue">commercially marketed</font> <font color="blue">in the US     </font>unless it has <font color="blue">been approved as safe</font> and <font color="blue">effective by</font> CVM Approval may be     <font color="blue">requested by filing</font> an NADA with CVM containing substantial <font color="blue">evidence as</font> to     the safety and <font color="blue">effectiveness</font> of the drug</td>
    </tr>
    <tr>
      <td>Data regarding <font color="blue">manufacturing</font>     methods  and <font color="blue">controls also</font> are required to be <font color="blue">submitted with</font> the NADA     Manufacturers of animal drugs must also comply with GMPs and Good Laboratory     Practices (“GLPs”)</td>
    </tr>
    <tr>
      <td>Sales of animal drugs in countries outside the US     require <font color="blue">compliance with</font> the laws of those countries, which may be extensive</td>
    </tr>
    <tr>
      <td>Water <font color="blue">testing products</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">water tests</font> are not subject to formal     premarket <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td>However, before a test can be used as part of     a water-quality <font color="blue">monitoring program</font> in the US that is required by the EPA,     the  test  must first be <font color="blue">approved by</font> <font color="blue">the EPA The EPA </font>approval process     <font color="blue">involves submission</font> of extensive <font color="blue"><font color="blue">product performance</font> data</font> in <font color="blue"><font color="blue">accordance</font> with</font>     an EPA-approved protocol, evaluation of the data by the EPA and publication     for public comment of any <font color="blue">proposed approval</font> in the Federal Register before     final  approval</td>
    </tr>
    <tr>
      <td>Our Colilert®, Colilert®-18, Colisure®, Quanti-Tray®,     Filta-Max® and SimPlate® for <font color="blue">heterotropic</font> plate counts (“HPC”) products have     <font color="blue">been <font color="blue">approved by</font></font> the EPA The sale of water-<font color="blue">testing products</font> also is subject     to extensive and lengthy <font color="blue">regulatory</font> processes in many other <font color="blue">countries around</font>     the world</td>
    </tr>
    <tr>
      <td>Dairy <font color="blue">testing products</font></td>
    </tr>
    <tr>
      <td>The sale of dairy <font color="blue">testing products</font> in the     US is <font color="blue">regulated by</font> the FDA in <font color="blue">conjunction</font> with the AOAC Research Institute     (“AOAC RI”)</td>
    </tr>
    <tr>
      <td>Before a product can be sold, extensive <font color="blue">product performance</font>     data must be submitted in <font color="blue"><font color="blue">accordance</font> with</font> a protocol that is <font color="blue">approved by</font> the     FDA and the AOAC RI <font color="blue">Following </font>approval of a <font color="blue">product by</font> the FDA, the product     must  also  be  <font color="blue">approved by</font> <font color="blue">the National Conference </font>on Interstate Milk     Shipments (“NCIMS”), an oversight body that includes state, federal and     industry <font color="blue">representatives</font></td>
    </tr>
    <tr>
      <td>Our dairy antibiotic residue <font color="blue">testing products</font> have     <font color="blue">been <font color="blue">approved by</font></font> the <font color="blue">FDA and NCIMS While </font>some <font color="blue"><font color="blue">foreign countries</font> accept</font> AOAC     RI <font color="blue">approval as</font> part of their <font color="blue">regulatory</font> approval process, many countries     have separate <font color="blue">regulatory</font> processes</td>
    </tr>
    <tr>
      <td>Any <font color="blue">acquisitions</font> of <font color="blue">new products</font> and <font color="blue">technologies</font> may subject us to     <font color="blue">additional areas</font> of <font color="blue">government regulation</font></td>
    </tr>
    <tr>
      <td>These may involve food, drug and     water-quality <font color="blue">regulations</font> of the FDA, the EPA and the USDA, as well as     state, local and <font color="blue">foreign governments</font></td>
    </tr>
    <tr>
      <td>See “Part I, Item 1A <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>We are not a party to any <font color="blue">collective bargaining</font>     <font color="blue">agreement</font> and we believe that <font color="blue">relations with</font> our employees are good</td>
    </tr>
    <tr>
      <td>8       _________________________________________________________________       ITEM 1A RISK FACTORS               Our  future  operating  results  involve a number of risks and     <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>Actual events or results <font color="blue">may differ materially from</font> those     discussed in this report</td>
    </tr>
    <tr>
      <td>Factors that could cause or contribute to such     <font color="blue">differences</font> include, but are not limited to, the <font color="blue">factors discussed</font> below, as     well as those <font color="blue">discussed elsewhere</font> in this report</td>
    </tr>
    <tr>
      <td>IDEXXapstas Future Growth and Profitability Depend on Several Factors                The <font color="blue">future success</font> of our business <font color="blue">depends upon</font> our ability to     <font color="blue">successfully</font> implement <font color="blue">various strategies</font>, including:       • Developing, <font color="blue">manufacturing</font> and marketing <font color="blue">new products</font> with new features and     <font color="blue">capabilities</font>, including <font color="blue"><font color="blue">pharmaceutical</font> products</font>; a <font color="blue">new clinical chemistry</font>     instrument; and rapid assay, water testing and <font color="blue">production animal <font color="blue">diagnostic</font></font>     products, as well as improving and enhancing existing products;       • <font color="blue">Developing </font>and <font color="blue">implementing</font> new <font color="blue">technology</font> and licensing strategies; and     identifying, completing and <font color="blue">integrating</font> <font color="blue">acquisitions</font> that enhance our     existing <font color="blue">businesses</font> or create new business areas for us;       • <font color="blue">Increasing </font>the value to our customers of our companion animal products and     services by enhancing the <font color="blue">connectivity</font> of these products, including the     <font color="blue">connectivity</font> among the IDEXX VetLab^® instrument suite, Cornerstone^®     practice information <font color="blue"><font color="blue">management</font> system</font>, the IDEXX-PACS™ software and IDEXX     Reference Laboratories;       • Expanding our <font color="blue">market by expanding</font> the <font color="blue">installed base</font> of our     <font color="blue">instrumentation through customer acquisition</font> and retention and increasing     use of our <font color="blue">products by</font> our customers;       • <font color="blue">Strengthening </font>our sales and marketing <font color="blue">activities</font> both within the US and     in <font color="blue">geographies</font> outside of the US; and       • Reducing the costs of <font color="blue">manufacturing</font> our products and providing services     through operating <font color="blue">efficiencies</font> and increased focus on quality</td>
    </tr>
    <tr>
      <td>However, we may not be able to <font color="blue">successfully</font> implement some or all of     these  strategies  and  increase  or  sustain  our  rate  of growth or     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Our  Products  and  Services Are Subject to Various Government     Regulations               In the US, the <font color="blue">manufacture</font> and sale of our products are regulated     by agencies such as the US Department of Agriculture (“USDA”), US Food     and Drug Administration (“FDA”) and the US Environmental Protection Agency     (“EPA”)</td>
    </tr>
    <tr>
      <td>Most <font color="blue"><font color="blue">diagnostic</font> tests</font> for animal <font color="blue">health applications</font>, including our     canine, feline, poultry and livestock tests, must be <font color="blue">approved by</font> the USDA     prior to sale</td>
    </tr>
    <tr>
      <td>Our <font color="blue">water <font color="blue">testing products</font></font> must be <font color="blue">approved by</font> the EPA before     they can be <font color="blue">used by customers</font> in the US as a part of a <font color="blue">water quality</font>     <font color="blue">monitoring program</font> required by the EPA Our <font color="blue">pharmaceutical</font> and <font color="blue">dairy testing</font>     products  require <font color="blue">approval by</font> the FDA The <font color="blue">manufacture</font> and sale of our     products are subject to similar laws in many <font color="blue">foreign countries</font></td>
    </tr>
    <tr>
      <td>Any failure     to <font color="blue">comply with legal</font> and <font color="blue">regulatory</font> <font color="blue">requirements</font> relating to the <font color="blue">manufacture</font>     and sale of our products in the US or in other <font color="blue">countries could</font> result in     fines and <font color="blue">sanctions against us</font> or removals of our <font color="blue">products from</font> the market,     <font color="blue">which could</font> have a material adverse effect on our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">entered into</font> an <font color="blue">agreement</font> with the FDA under which we have     agreed, among other things, to perform specified lot release and stability     testing of our SNAP® beta-lactam dairy-<font color="blue">testing products</font> and to provide     related data to the <font color="blue">FDA If the FDA </font>were to determine that one or more lots     of <font color="blue">product failed</font> to <font color="blue">meet applicable criteria</font> for <font color="blue">product performance</font> or     stability, the FDA could take <font color="blue">various actions</font>, including requiring us to     <font color="blue">recall products</font> or restricting our ability to sell these products</td>
    </tr>
    <tr>
      <td>Sales of     dairy antibiotic residue-<font color="blue">testing products</font> were dlra15dtta6 million for the year     ended <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td><font color="blue">Commercialization </font>of animal health <font color="blue"><font color="blue">pharmaceutical</font>s</font> <font color="blue">in the US     </font>requires  prior  <font color="blue">approval by</font> the FDA To obtain <font color="blue">such approvals</font>, we are     required to submit substantial clinical, <font color="blue">manufacturing</font> and other data to the     <font color="blue">FDA Regulatory </font>approval for <font color="blue">products submitted</font> to the FDA may take several     years and, <font color="blue">following approval</font>, the FDA continues to regulate all aspects of     the  <font color="blue">manufacture</font>,  labeling,  storage, record keeping and promotion of     <font color="blue"><font color="blue">pharmaceutical</font> products</font></td>
    </tr>
    <tr>
      <td>Failure to obtain, or delays in obtaining, FDA     approval for new <font color="blue"><font color="blue">pharmaceutical</font> products</font> would have a <font color="blue">negative <font color="blue">impact on</font></font> our     <font color="blue">future growth</font></td>
    </tr>
    <tr>
      <td>9       _________________________________________________________________               <font color="blue">We Purchase Materials for Our Products </font>from a <font color="blue">Limited Number </font>of     Sources               We  <font color="blue">currently purchase</font> many products and <font color="blue">materials from single</font>     sources  or  a limited number of sources</td>
    </tr>
    <tr>
      <td>Some of the products that we     <font color="blue">purchase from</font> these sources are <font color="blue">proprietary</font>, and, therefore, cannot be     readily  replaced  by  <font color="blue">alternative sources</font></td>
    </tr>
    <tr>
      <td>These products include our     VetTest^® Chemistry, VetAutoread™ Hematology, VetLyte^® Electrolyte, and     VetStat™  Electrolyte and Blood Gas Analyzers and related <font color="blue">consumables</font>;     certain digital <font color="blue">radiography</font> system <font color="blue">components</font>, <font color="blue">specifically</font> image capture     plates and readers; <font color="blue">active <font color="blue">ingredients</font></font> for <font color="blue"><font color="blue">pharmaceutical</font> products</font>; and     certain <font color="blue">components</font> of our SNAP^® <font color="blue">rapid assay devices</font>, <font color="blue">water <font color="blue">testing products</font></font>     and LaserCyte^® Hematology Analyzers</td>
    </tr>
    <tr>
      <td>If we are unable to obtain adequate     quantities of these products in the future, we <font color="blue">could face cost increases</font> or     <font color="blue">reductions</font> or delays in product shipments, <font color="blue">which could</font> have a material     adverse effect on our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">slides sold</font> for use in our VetTest^® Chemistry Analyzers are     <font color="blue">purchased under</font> an <font color="blue">agreement</font> with Ortho that, as of <font color="blue">December </font>31, 2005,     required us to purchase a minimum of dlra92dtta7 million of slides through 2010</td>
    </tr>
    <tr>
      <td>We purchase our electrolyte instruments, <font color="blue">components</font> and <font color="blue">consumables</font> under an     <font color="blue">agreement</font> with Roche Diagnostics, under which we are required to purchase a     minimum of dlra4dtta1 million of these products through 2006</td>
    </tr>
    <tr>
      <td>We purchase our     VetAutoread™ Hematology Analyzers, <font color="blue">components</font> and <font color="blue">consumables</font> under an     <font color="blue">agreement</font> with QBCD, under which we are required to make <font color="blue">aggregate minimum</font>     purchases of dlra18dtta0 million through 2020</td>
    </tr>
    <tr>
      <td>If demand for any of the products     <font color="blue">purchased under</font> these <font color="blue">agreement</font>s is insufficient to support our minimum     <font color="blue">purchase <font color="blue">obligations</font></font> for those products, we <font color="blue">could incur losses</font> related to     those  <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>In  addition, because we purchase the <font color="blue">products at</font>     <font color="blue">predetermined prices</font>, our <font color="blue">profits on sales</font> of these <font color="blue">products could decline</font>     if we are unable to maintain <font color="blue">current pricing levels</font> for <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>Our Biologic Products Are Complex and Difficult to Manufacture               Many of our rapid assay and production animal <font color="blue"><font color="blue">diagnostic</font> products</font>     are biologics, which are products that are comprised of materials from     living organisms, such as <font color="blue">antibodies</font>, cells and sera</td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturing </font>biologic     products is <font color="blue">highly complex</font></td>
    </tr>
    <tr>
      <td>Unlike products that <font color="blue">rely on chemicals</font> for     efficacy  (such  as  most <font color="blue"><font color="blue">pharmaceutical</font>s</font>), biologics are <font color="blue">difficult</font> to     <font color="blue">characterize due</font> to the <font color="blue">inherent variability</font> of <font color="blue">biological input materials</font></td>
    </tr>
    <tr>
      <td><font color="blue">Difficulty </font>in <font color="blue">characterizing</font> biological materials or their <font color="blue">interactions</font>     creates greater risk in the <font color="blue">manufacturing</font> process</td>
    </tr>
    <tr>
      <td>We attempt to mitigate     <font color="blue">risk associated with</font> the <font color="blue">manufacture</font> of <font color="blue">biologics by continuing</font> to improve     the <font color="blue">characterization</font> of all of our input materials, utilizing multiple     vendors, <font color="blue">manufacturing</font> some of these <font color="blue">materials ourselves</font> and maintaining     substantial <font color="blue">inventories</font> of materials that have <font color="blue">demonstrated</font> the <font color="blue">appropriate</font>     <font color="blue">characteristics</font></td>
    </tr>
    <tr>
      <td>However, there can be no assurance that we will be able to     maintain  adequate  sources of biological materials or that biological     materials that we maintain in <font color="blue">inventory will yield</font> finished products that     satisfy  applicable  <font color="blue">product release criteria</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to obtain     <font color="blue">necessary biological materials</font> or to <font color="blue">successfully</font> <font color="blue">manufacture</font> biologic     products that <font color="blue">incorporate such materials could</font> have a material adverse     effect on our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our Success Is Heavily Dependent Upon Our Proprietary Technologies               We rely on a <font color="blue">combination</font> of patent, trade secret, trademark and     <font color="blue">copyright laws</font> to protect our <font color="blue">proprietary</font> rights</td>
    </tr>
    <tr>
      <td>If we do not have adequate     protection  of our <font color="blue">proprietary</font> rights, our business may be <font color="blue">affected by</font>     <font color="blue">competitors</font> who develop <font color="blue">substantially</font> equivalent <font color="blue">technologies</font> that compete     with us</td>
    </tr>
    <tr>
      <td>We  <font color="blue">cannot ensure</font> that we will obtain <font color="blue">issued patents</font>, that any     <font color="blue">patents issued</font> or licensed to <font color="blue">us will remain valid</font>, or that any patents     owned or licensed by us will provide protection against <font color="blue">competitors</font> with     similar  <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Even if our <font color="blue">patents cover products sold by</font> our     <font color="blue">competitors</font>, the time and expense of litigating to enforce our <font color="blue">patent rights</font>     could  be substantial, and could have a material adverse effect on our     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, expiration of <font color="blue">patent rights</font> could result     in  substantial <font color="blue">new competition</font> in the markets for <font color="blue">products previously</font>     <font color="blue">covered by</font> those <font color="blue">patent rights</font></td>
    </tr>
    <tr>
      <td>In the past, we have received notices claiming that our products     infringe third-party patents and we may receive such notices in the future</td>
    </tr>
    <tr>
      <td>Patent  <font color="blue">litigation</font> is complex and expensive, and the outcome of patent     <font color="blue">litigation</font> can be <font color="blue">difficult</font> to predict</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot ensure</font> that we will win a     patent <font color="blue">litigation</font> case or negotiate an acceptable resolution of such a case</td>
    </tr>
    <tr>
      <td>If we lose, we may be stopped from selling certain products and/or we may be     required to pay damages and/or ongoing royalties as a result of the lawsuit</td>
    </tr>
    <tr>
      <td>Any <font color="blue">such adverse</font> result could have a material adverse effect on our results     of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>10       _________________________________________________________________               <font color="blue">Our Sales Are Dependent </font>on Distributor Purchasing Patterns                We sell many of our products, including <font color="blue">substantially</font> all of the     rapid  assays  and  instrument  <font color="blue">consumables</font>  sold in the US, through     <font color="blue"><font color="blue">distributor</font>s</font></td>
    </tr>
    <tr>
      <td>Because <font color="blue">significant product sales</font> are made to a limited number     of customers, unanticipated changes in the timing and size of <font color="blue">distributor</font>     purchases can have a negative effect <font color="blue">on quarterly</font> results</td>
    </tr>
    <tr>
      <td>Our financial     performance, therefore, is subject to an <font color="blue">unexpected downturn</font> in product     demand and may be unpredictable</td>
    </tr>
    <tr>
      <td><font color="blue">Distributors </font>of <font color="blue">veterinary</font> products have <font color="blue">entered into</font> business     <font color="blue">combination</font>s resulting in fewer <font color="blue">distribution</font> companies</td>
    </tr>
    <tr>
      <td><font color="blue">Consolidation </font>within     <font color="blue"><font color="blue">distribution</font> channels</font> would increase our customer concentration level, which     <font color="blue">could increase</font> the <font color="blue">risks described</font> in the <font color="blue">preceding paragraph</font></td>
    </tr>
    <tr>
      <td>Our Markets Are <font color="blue">Competitive </font>and Subject to Rapid and Substantial     Technological Change                We <font color="blue">face intense competition within</font> the markets in which we sell our     products and services</td>
    </tr>
    <tr>
      <td>We expect that <font color="blue">future competition will become even</font>     more intense, and that we will have to <font color="blue">compete with</font> changing and improving     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Some of our <font color="blue">competitors</font> and potential <font color="blue">competitors</font>, including     large <font color="blue">pharmaceutical</font> and <font color="blue">diagnostic</font> companies, have <font color="blue">substantially</font> greater     capital, <font color="blue">manufacturing</font>, marketing, and research and <font color="blue">development</font> resources     than we do</td>
    </tr>
    <tr>
      <td>Changes in Diagnostic Testing Could Negatively Affect Our Operating     Results               The market for <font color="blue"><font color="blue">diagnostic</font> tests</font> could be <font color="blue">negatively impacted by</font> the     <font color="blue">introduction</font> or <font color="blue">broad market acceptance</font> of vaccines or <font color="blue">preventatives</font> for the     diseases and <font color="blue">conditions</font> for which we sell <font color="blue"><font color="blue">diagnostic</font> tests</font> and services</td>
    </tr>
    <tr>
      <td><font color="blue">Eradication </font>or substantial declines in the prevalence of <font color="blue">certain diseases</font>     <font color="blue">also could lead</font> to a decline in <font color="blue">diagnostic</font> testing for <font color="blue">such diseases</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">production animal services</font> business in particular is subject to <font color="blue">fluctuations</font>     resulting from changes in <font color="blue">disease prevalence</font> and government-mandated testing     programs</td>
    </tr>
    <tr>
      <td>Such declines in <font color="blue">diagnostic</font> testing could have a material adverse     effect on our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>International Revenue Accounts for a <font color="blue">Significant </font>Portion of Our     Total Revenue               For  the  year ended <font color="blue">December </font>31, 2005, 34prca of our revenue was     <font color="blue">attributable</font> to sales of products and services to <font color="blue">customers outside</font> the US     Various  risks  associated  with  foreign  <font color="blue">operations</font>  may  impact our     <font color="blue">international sales</font></td>
    </tr>
    <tr>
      <td>Possible risks include <font color="blue">fluctuations</font> in the value of     <font color="blue">foreign currencies</font>, disruptions in <font color="blue">transportation</font> of our products, the     <font color="blue">differing product</font> and service needs of foreign customers, <font color="blue">difficult</font>ies in     building and managing foreign <font color="blue">operations</font>, import/export duties and quotas,     and unexpected <font color="blue">regulatory</font>, economic or political changes in <font color="blue">foreign markets</font></td>
    </tr>
    <tr>
      <td>Prices that we charge to foreign customers may be <font color="blue">different</font> than the prices     we charge for the <font color="blue">same products</font> in the US due to competitive, market or     other factors</td>
    </tr>
    <tr>
      <td>As a result, the mix of domestic and <font color="blue">international sales</font> in a     <font color="blue">particular period could</font> have a material <font color="blue">impact on</font> our results for that     period</td>
    </tr>
    <tr>
      <td>In addition, many of the products for which our <font color="blue">selling price may</font> be     <font color="blue">denominated</font> in <font color="blue">foreign currencies</font> are <font color="blue"><font color="blue">manufacture</font>d</font>, sourced, or both, in the     US and our costs are incurred in US dollars</td>
    </tr>
    <tr>
      <td>We <font color="blue">utilize nonspeculative</font>     <font color="blue">forward currency exchange contracts</font> to <font color="blue">mitigate foreign currency exposure</font>,     however,  an  <font color="blue">appreciation</font>  <font color="blue">of the US </font><font color="blue">dollar relative</font> to the foreign     currencies  in which we sell these <font color="blue">products would reduce</font> our operating     margins</td>
    </tr>
    <tr>
      <td>The Loss of Our President, Chief Executive Officer and Chairman Could     Adversely Affect Our Business               We rely on the <font color="blue">management</font> and <font color="blue">leadership</font> of Jonathan W Ayers, our     President, Chief Executive Officer and Chairman</td>
    </tr>
    <tr>
      <td>We do not maintain key man     <font color="blue">life insurance coverage</font> for Mr</td>
    </tr>
    <tr>
      <td>Ayers could have a     material <font color="blue">impact on</font> our business</td>
    </tr>
    <tr>
      <td>11       _________________________________________________________________         We Could Be Subject to Class Action Litigation Due to Stock Price     Volatility, which, if Occurs, Could Result in Substantial Costs or Large     Judgments Against Us                The market for our <font color="blue">common stock may</font> experience <font color="blue">extreme price</font> and     volume <font color="blue">fluctuations</font>, which may be unrelated or <font color="blue">disproportionate</font> to our     operating performance or prospects</td>
    </tr>
    <tr>
      <td>In the past, securities class action     <font color="blue">litigation</font> has often been brought against companies following periods of     <font color="blue">volatility</font> in the <font color="blue">market prices</font> of their securities</td>
    </tr>
    <tr>
      <td>We may be the target of     similar <font color="blue">litigation</font> in the future</td>
    </tr>
    <tr>
      <td><font color="blue">Securities </font><font color="blue">litigation</font> could result in     substantial costs and divert our <font color="blue">management</font>’s attention and resources, which     could  have  a  negative effect on our business, operating results and     <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>If Our Quarterly Results of Operations Fluctuate, This Fluctuation May     Cause Our Stock Price to Decline, Resulting in Losses to You                Our prior operating results have <font color="blue">fluctuated due</font> to a number of     factors, including <font color="blue">seasonality</font> of certain <font color="blue">product line</font>s; changes in our     <font color="blue">accounting</font> estimates; the impact of <font color="blue">acquisitions</font>; timing of <font color="blue">distributor</font>     purchases,  product  launches,  research and <font color="blue">development</font> expenditures,     <font color="blue">litigation</font> and claim-related expenditures; changes in <font color="blue">competitors</font>’ product     offerings; and other matters</td>
    </tr>
    <tr>
      <td>Similarly, our future operating results may     <font color="blue">vary significantly from quarter</font> to <font color="blue">quarter due</font> to these and other factors,     many  of  which  are  beyond  our control</td>
    </tr>
    <tr>
      <td>If our operating results or     <font color="blue">projections</font> of future operating results do not meet the <font color="blue">expectations</font> of     <font color="blue">market analysts</font> or investors in <font color="blue">future periods</font>, our <font color="blue">stock price may fall</font></td>
    </tr>
    <tr>
      <td>Future Operating Results Could Be Materially Affected By the Resolution of     Various Uncertain Tax Positions and Adversely Affected by Potential Changes     to Tax Incentives                In the ordinary course of our business, there are many <font color="blue">transactions</font>     and  <font color="blue">calculations</font>  where  the ultimate tax <font color="blue">determination</font> is uncertain</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>judgment is required in determining our <font color="blue">worldwide provision</font> for     <font color="blue">income taxes</font> and our <font color="blue">income tax filings</font> are <font color="blue">regularly under audit by tax</font>     <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>We believe that we have <font color="blue">adequately accrued</font> for all potential     tax liabilities and, although we believe our tax estimates are reasonable,     the final <font color="blue">determination</font> of <font color="blue">tax audits could</font> be materially <font color="blue">different</font> than     that which is reflected in <font color="blue">historical income tax provisions</font> and accruals</td>
    </tr>
    <tr>
      <td>Additionally, we benefit from certain tax incentives offered by various     <font color="blue">jurisdictions</font></td>
    </tr>
    <tr>
      <td>If we are unable to meet the <font color="blue">requirements</font> of <font color="blue">such incentives</font>,     our <font color="blue">inability</font> to use these <font color="blue">benefits could</font> have a material negative effect on     <font color="blue">future earnings</font></td>
    </tr>
  </tbody>
</table>